175 results found
Rice T, Diavatopoulos D, Smits G, et al., Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy- a prospective, observational cohort study from the UK, Clinical and Experimental Immunology, ISSN: 1365-2249
Zhong Z, Haltalli M, Holder B, et al., 2019, The impact of timing of maternal influenza immunization on infant antibody levels at birth, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, Vol: 195, Pages: 139-152, ISSN: 0009-9104
Rachow A, Ivanova O, Wallis R, et al., 2019, TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB - a study protocol, BMC PULMONARY MEDICINE, Vol: 19, ISSN: 1471-2466
Lindsey BB, Armitage EP, Kampmann B, et al., 2018, The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review., Lancet Infect Dis
The burden of influenza in Africa is substantial and underappreciated. Although surveillance has increased, the medical community's understanding of seasonal influenza vaccine performance remains limited. We did a systematic review, using PRISMA guidelines (PROSPERO CRD42017058107), on the efficacy, effectiveness, and immunogenicity of influenza vaccines in populations within Africa with the aim of identifying key data gaps to help direct future research. We searched Embase, MEDLINE, Global Health database, and Web of Science for published studies from database inception to May 9, 2018. Unpublished studies were identified by searching ClinicalTrials.gov and the Pan-African Clinical Trial Registry, and by contacting experts within the field. Human studies that reported influenza vaccine immunogenicity, effectiveness, and efficacy were included. 1746 articles were assessed and 23 articles were included. Only three of the 23 studies were of high quality and many studies were underpowered. All 23 studies came from only six African countries (16 from South Africa), highlighting the need for data from a broader range of African populations. The majority of studies focused on effectiveness or efficacy against laboratory supported influenza with limited data for severe outcomes. Several factors known to interfere with influenza immunisation, such as malaria, HIV, and malnutrition were under-represented in this Review and require further study. Substantial gaps exist in our understanding of influenza vaccine performance across all WHO high-risk groups in Africa. Filling these knowledge gaps is vital to guide future influenza vaccine policies.
Seddon J, Whittaker E, Kampmann B, et al., The Evolving Research Agenda for Paediatric Tuberculosis Infection, Lancet Infectious Diseases, ISSN: 1473-3099
Munoz FM, Van Damme P, Dinleyici E, et al., 2018, The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward Integrating Maternal and Infant Immunization Programs, MSPHERE, Vol: 3, ISSN: 2379-5042
Keshavjee S, Amanullah F, Cattamanchi A, et al., 2018, Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection., Am J Respir Crit Care Med
Tuberculosis (TB) has surpassed HIV to become the leading infectious killer of adults globally, causing almost 2 million deaths annually. Although this airborne disease has been treatable since 1948, global rates of TB have dropped less than two percent per year; an estimated 10 million incident cases continue to occur annually, including one million in children. While transmission of active disease is an important driver of the epidemic, the seedbed that feeds the epidemic is the more than two billion people estimated to have TB infection, five to ten percent of whom will progress to active disease during their lifetime. While any successful strategy aimed at TB elimination needs to address this reservoir of TB infection worldwide, much remains to be understood about host and pathogen factors that can be used to identify increased risk for progression to disease, and intervened upon to prevent progression from occurring. The Division of AIDS of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA, and the Harvard Medical School Center for Global Health Delivery-Dubai convened a group of scientists and stakeholders on September 28 and 29, 2017, to address knowledge gaps that affect our ability to rapidly find and treat individuals infected with Mycobacterium tuberculosis who are most likely to progress to active disease. The meeting identified a number of efforts underway to address this important gap in the collective ability to stop the global TB epidemic. Here, we review and outline the priority areas for research, diagnosis and treatment of TB infection that emerged from the meeting (Table 1), building on recent reviews in this area.
Whittaker E, Nicol MP, Zar HJ, et al., 2018, Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322
Basu Roy R, Whittaker E, Seddon JA, et al., 2018, Tuberculosis susceptibility and protection in children., Lancet Infect Dis
Children represent both a clinically important population susceptible to tuberculosis and a key group in whom to study intrinsic and vaccine-induced mechanisms of protection. After exposure to Mycobacterium tuberculosis, children aged under 5 years are at high risk of progressing first to tuberculosis infection, then to tuberculosis disease and possibly disseminated forms of tuberculosis, with accompanying high risks of morbidity and mortality. Children aged 5-10 years are somewhat protected, until risk increases again in adolescence. Furthermore, neonatal BCG programmes show the clearest proven benefit of vaccination against tuberculosis. Case-control comparisons from key cohorts, which recruited more than 15 000 children and adolescents in total, have identified that the ratio of monocytes to lymphocytes, activated CD4 T cell count, and a blood RNA signature could be correlates of risk for developing tuberculosis. Further studies of protected and susceptible populations are necessary to guide development of novel tuberculosis vaccines that could facilitate the achievement of WHO's goal to eliminate deaths from tuberculosis in childhood.
Bah SY, Forster T, Dickinson P, et al., 2018, Meta-Analysis Identification of Highly Robust and Differential Immune-Metabolic Signatures of Systemic Host Response to Acute and Latent Tuberculosis in Children and Adults, FRONTIERS IN GENETICS, Vol: 9, ISSN: 1664-8021
Praharaj I, Parker EPK, Giri S, et al., 2018, Influence of non-polio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from south India., J Infect Dis
Background: Oral poliovirus vaccine (OPV) is less immunogenic in LMIC countries. We tested whether bacterial and viral components of the intestinal microbiota are associated with this phenomenon. Methods: We assessed prevalence of enteropathogens using TaqMan array cards 14 days before and at vaccination in 704 Indian infants (6-11 months) receiving monovalent type3 OPV (CTRI/2014/05/004588). Non-polio enterovirus (NPEV) serotypes were identified by VP1 sequencing. In 120 infants, pre-vaccination bacterial microbiota was characterised by 16S rRNA sequencing. Results: We detected 56 NPEV serotypes on the day of vaccination. Concurrent NPEVs were associated with a reduction in OPV seroconversion, consistent across species (odds ratios and 95% CIs of 0·57[0·36-0·90], 0·61[0·43-0·86], and 0·69[0·41-1·16] for species A, B, and C, respectively). Recently acquired enterovirus infections,detected at vaccination, but not 14 days earlier had greater interfering effect on mOPV3 sero-response compared to persistent infections,with enterovirus detected at both time points (44/127[35%] vs 63/129[49%] seroconversion,p=0.021). Abundance of specific bacterial taxa did not differ significantly according to OPV response, although microbiota diversity was higher in non-responders at the time of vaccination. Conclusion: Enteric viruses have greater impact on OPV response than the bacterial microbiota with recent enterovirus infections having greater inhibitory effect than persistent infections.
Rice TF, Donaldson B, Bouqueau M, et al., 2018, Macrophage- but not monocyte-derived extracellular vesicles induce placental pro-inflammatory responses, PLACENTA, Vol: 69, Pages: 92-95, ISSN: 0143-4004
Whittaker EA, Nicol M, Zar H, et al., Evidence of waning BCG responses in healthy children; time to introduce a booster?, Scientific Reports, ISSN: 2045-2322
Usuf E, Mackenzie G, Ceesay L, et al., 2018, Vaccine wastage in The Gambia: a prospective observational study, BMC PUBLIC HEALTH, Vol: 18, ISSN: 1471-2458
Harausz EP, Garcia-Prats AJ, Law S, et al., 2018, Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis, PLOS MEDICINE, Vol: 15, ISSN: 1549-1676
Kampmann B, Seddon JA, Paton J, et al., 2018, Evaluating UK National Guidance for Screening of Children for Tuberculosis A Prospective Multicenter Study, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 197, Pages: 1058-1064, ISSN: 1073-449X
Armitage ET, Camara J, Bah S, et al., 2018, Acceptability of intranasal live attenuated influenza vaccine; influenza knowledge and vaccine intent in The Gambia, VACCINE, Vol: 36, Pages: 1772-1780, ISSN: 0264-410X
Parker EPK, Praharaj I, Zekavati A, et al., 2018, Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India, VACCINE, Vol: 36, Pages: 264-272, ISSN: 0264-410X
Nonyane BAS, Nicol MP, Andreas NJ, et al., 2018, Serologic Responses in Childhood Pulmonary Tuberculosis, PEDIATRIC INFECTIOUS DISEASE JOURNAL, Vol: 37, Pages: 1-9, ISSN: 0891-3668
Mensah VA, Roetynck S, Kanteh EK, et al., 2017, Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial, FRONTIERS IN IMMUNOLOGY, Vol: 8, ISSN: 1664-3224
Le Doare K, O'Driscoll M, Turner K, et al., 2017, Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review, CLINICAL INFECTIOUS DISEASES, Vol: 65, Pages: S143-S151, ISSN: 1058-4838
Hemingway C, Berk M, Anderson ST, et al., 2017, Childhood tuberculosis is associated with decreased abundance of T cell gene transcripts and impaired T cell function, PLOS ONE, Vol: 12, ISSN: 1932-6203
Saso A, Kampmann B, 2017, Vaccine responses in newborns, SEMINARS IN IMMUNOPATHOLOGY, Vol: 39, Pages: 627-642, ISSN: 1863-2297
Saso A, Donaldson B, Kampmann B, 2017, Uptake of Pertussis and Influenza Vaccinations in Pregnancy, Publisher: SPRINGER, Pages: 1508-1508, ISSN: 0340-6199
Le Doare K, Bellis K, Faal A, et al., 2017, SIgA, TGF-beta 1, IL-10, and TNF alpha in Colostrum Are Associated with Infant Group B Streptococcus Colonization, FRONTIERS IN IMMUNOLOGY, Vol: 8, ISSN: 1664-3224
de Silva TI, Gould V, Mohammed NI, et al., 2017, Comparison of mucosal lining fluid sampling methods and influenza-specific IgA detection assays for use in human studies of influenza immunity, JOURNAL OF IMMUNOLOGICAL METHODS, Vol: 449, Pages: 1-6, ISSN: 0022-1759
Turkova A, Kampmann B, 2017, Short course treatment for MDR TB: jumping the gun?, THORAX, Vol: 72, Pages: 773-773, ISSN: 0040-6376
Bibby J, Saidu Y, Umesi A, et al., 2017, The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb, CLINICAL INFECTIOUS DISEASES, Vol: 65, Pages: 851-854, ISSN: 1058-4838
Parker EPK, Praharaj I, John J, et al., 2017, Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322
Heath PT, Culley FJ, Jones CE, et al., 2017, Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis, LANCET INFECTIOUS DISEASES, Vol: 17, Pages: E223-E234, ISSN: 1473-3099
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.